Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab after chemoradiotherapy in stage III NSCLC
NCT04392505Phase 2Active, not recruiting
- Sponsor
- Oslo University Hospital
- Start
- May 2020
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 4
01
Overview
Phase 2, open-label trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Oslo University Hospital. Primary endpoint: Impact of tumour mutational burden (TMB) on the hazard at 5 years. Started May 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04392505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392505.